ST葫芦娃：吸入用异丙托溴铵溶液获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the inhalation solution of ipratropium bromide, indicating a significant advancement in its product portfolio for respiratory diseases [1] Group 1: Product Approval - The inhalation solution of ipratropium bromide is approved in two dosages: 2ml with 0.25mg for treating reversible airway obstruction caused by acute or chronic asthma, and 2ml with 0.5mg as a bronchodilator for chronic obstructive pulmonary disease (COPD) [1] - The product can be used in conjunction with inhaled β-agonists for treating acute bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and asthma [1] Group 2: Research and Development Investment - The company has invested a total of 5.9089 million yuan (approximately 0.59 million) in the research and development of this product, which is not audited [1]